Human Cytomegalovirus Envelope Glycoprotein B Market

Human Cytomegalovirus Envelope Glycoprotein B Market contains market size and forecasts of Human Cytomegalovirus Envelope Glycoprotein B in global, including the following market information:
Global Human Cytomegalovirus Envelope Glycoprotein B Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Human Cytomegalovirus Envelope Glycoprotein B Market Sales, 2017-2022, 2023-2028, (K Pcs)
Global top five Human Cytomegalovirus Envelope Glycoprotein B companies in 2021 (%)
The global Human Cytomegalovirus Envelope Glycoprotein B market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
CSJ-148 Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Human Cytomegalovirus Envelope Glycoprotein B include Astellas Pharma Inc., Trellis Bioscience, Inc., Vakzine Projekt Management GmbH, VBI Vaccine Inc and Vical Incorporated, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Human Cytomegalovirus Envelope Glycoprotein B manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Human Cytomegalovirus Envelope Glycoprotein B Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Human Cytomegalovirus Envelope Glycoprotein B Market Segment Percentages, by Type, 2021 (%)
CSJ-148
CyMVectin
TRL-345
PPCM
Cytomegalovirus Vaccine
Others
Global Human Cytomegalovirus Envelope Glycoprotein B Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Human Cytomegalovirus Envelope Glycoprotein B Market Segment Percentages, by Application, 2021 (%)
Infectious Disease
Oncology
Women's Health
Others
Global Human Cytomegalovirus Envelope Glycoprotein B Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Pcs)
Global Human Cytomegalovirus Envelope Glycoprotein B Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Human Cytomegalovirus Envelope Glycoprotein B revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Human Cytomegalovirus Envelope Glycoprotein B revenues share in global market, 2021 (%)
Key companies Human Cytomegalovirus Envelope Glycoprotein B sales in global market, 2017-2022 (Estimated), (K Pcs)
Key companies Human Cytomegalovirus Envelope Glycoprotein B sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Astellas Pharma Inc.
Trellis Bioscience, Inc.
Vakzine Projekt Management GmbH
VBI Vaccine Inc
Vical Incorporated